Kraus M L, Gottlieb L D, Horwitz R I, Anscher M
N Engl J Med. 1985 Oct 10;313(15):905-9. doi: 10.1056/NEJM198510103131501.
We conducted a randomized, double-blind clinical trial of atenolol as compared with placebo in the treatment of patients hospitalized with the alcohol withdrawal syndrome. In addition to receiving customary therapy, 61 patients were randomly assigned to receive atenolol, and 59 to receive placebo. Outcome was assessed daily by the measurement of nine features in three categories: vital signs, clinical signs (e.g., tremor), and behavioral signs (e.g., agitation and anxiety). Compared with placebo patients, atenolol patients had a significant reduction in the mean length of hospital stay (four as compared with five days, P less than 0.02). On each treatment day, significantly fewer patients receiving atenolol required concomitant benzodiazepines, and patients receiving placebo required a significantly higher mean daily dose of benzodiazepines. Among patients who had withdrawal symptoms at base line, vital signs became normal more rapidly in the patients receiving atenolol, and their abnormal behavior and clinical characteristics also resolved more rapidly. We conclude that atenolol is helpful in the treatment of patients with the alcohol withdrawal syndrome.
我们进行了一项随机、双盲临床试验，比较阿替洛尔与安慰剂治疗酒精戒断综合征住院患者的效果。除接受常规治疗外，61例患者被随机分配接受阿替洛尔治疗，59例接受安慰剂治疗。通过测量三类九个特征每日评估结果：生命体征、临床体征（如震颤）和行为体征（如激动和焦虑）。与接受安慰剂的患者相比，接受阿替洛尔治疗的患者平均住院时间显著缩短（分别为4天和5天，P<0.02）。在每个治疗日，接受阿替洛尔治疗的患者需要同时使用苯二氮䓬类药物的人数显著减少，而接受安慰剂治疗的患者所需苯二氮䓬类药物的平均每日剂量显著更高。在基线时有戒断症状的患者中，接受阿替洛尔治疗的患者生命体征恢复正常的速度更快，其异常行为和临床特征也更快得到缓解。我们得出结论，阿替洛尔有助于治疗酒精戒断综合征患者。
